Cystic Fibrosis Foundation
6931 Arlington Road
47 articles with Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants, which provide up to $10,000 of funding per year for up to two years to individuals and nonprofit organizations within the cystic fibrosis community who are leading projects to support people living with the disease.
The Cystic Fibrosis Foundation announced the initiation of the HERO-2: Home Reported Outcomes Study, a first-of-its-kind, at-home observational study that aims to characterize the range of outcomes people experience while using Trikafta®.
New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations
SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. The company plans to use the money to advance its pipeline.
Company to use its novel gene editing technology to explore a potential in vivo gene therapy treatment for cystic fibrosis
The Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.
the Cystic Fibrosis Registry Global Harmonization Group, including the Cystic Fibrosis Foundation, published findings from the first global study on the impact of COVID-19 on children with cystic fibrosis.
the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.
The Cystic Fibrosis Registry Global Harmonization Group, including the CF Foundation, published in the Journal of Cystic Fibrosis updated data on the impact of COVID-19 on people with cystic fibrosis.
Today, the Cystic Fibrosis Foundation announced a new research award of up to $2.4 million to Calithera Biosciences Inc. to advance a potential treatment to reduce infections in the lungs of people with cystic fibrosis. Individuals with CF who have chronic infections are at greater risk for worsening, life-threatening lung disease,
CF Foundation Commits up to $14 Million in Funding to Expand Research Agreement With Synspira Therapeutics
Today, the Cystic Fibrosis Foundation announced it is expanding its research collaboration with Synspira Therapeutics Inc., committing up to $14 million in additional funding to develop a non-porcine enzyme replacement therapy and a novel treatment to help fight drug-resistant infections. The new fun
33 Organizations Representing Millions of Patients Urge Policymakers to Adopt "Patient-First" Policy Agenda
A coalition of 33 organizations representing millions of people with pre-existing conditions launched an unprecedented effort by releasing their top priorities for the next Administration.
Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis
The Cystic Fibrosis Foundation announced a collaboration with Longwood Fund, a biotech-focused venture capital firm, to accelerate innovative therapies for cystic fibrosis.
CF Foundation Invests up to $14M in Effort to Solve Key Challenges to Gene Delivery in Cystic Fibrosis
The Cystic Fibrosis Foundation announced an investment of up to $14 million in 4D Molecular Therapeutics to develop a customized vehicle to deliver a healthy cystic fibrosis transmembrane conductance regulator gene into the lung cells of people with cystic fibrosis.
4D Molecular Therapeutics, a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced a new agreement with Cystic Fibrosis Foundation to develop precision gene medicines for cystic fibrosis.
Microbion Awarded up to $17.1 Million from CARB-X and the Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF
Potential first in a new class of antimicrobial drugs shown to have potent activity against CF-related pathogens in the lab
Collaborative effort identifies 40 cases of COVID-19 across eight countries; outcomes for this high-risk population were reported in the Journal of Cystic Fibrosis
Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement to Develop Broad-spectrum Enzyme Replacement for Malabsorption Syndromes
FRAMINGHAM, Mass. , Feb. 12, 2020 /PRNewswire/ -- Synspira Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases, announced today the company has signed an agreement with the Cystic Fibrosis Foundation to support the development of SNSP003, Synspira's orally delivered non-porci
Groupware Technology, Inc. announced it is the recipient of the Corporate Breath Award from the Northern California Chapter of the Cystic Fibrosis Foundation.